Related Experiment Video
Updated: Feb 10, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
Published on: October 20, 2023
Modelling neurodegeneration in prion disease - applications for drug development
Kay M Uppington1, David R Brown
1University of Bath, Department of Biology and Biochemistry, Bath, Claverton Down, BA2 7AY, UK +44 1255 383133 ; +44 1225 386779 ; bssdrb@bath.ac.uk.
Abstract:
Prion diseases are a group of neurodegenerative diseases that affect mammals, including humans and ruminants such as sheep. They are believed to be caused by the conversion of the prion protein (PrP), a host expressed protein, into a toxic form (PrP(sc)). PrP(sc) accumulates in the brain, resulting in neuronal loss and the typical spongiform appearance of the brain. So far, there are no effective therapies available for prion diseases. This review discusses possible therapies for prion diseases and the models available for advancing research into the disease.
Related Concept Videos
In Vitro Drug Release Testing: Overview, Development and Validation
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

